1 Title

3

7

12

15

18

26

- 2 Immunochromatographic test for the detection of SARS-CoV-2 in saliva
- 4 Authors
- 5 Katsuhito Kashiwagi¹, Yoshikazu Ishii², Kotaro Aoki², Shintaro Yagi^{3*}, Tadashi Maeda¹,
- Taito Miyazaki¹, Sadako Yoshizawa^{1,2}, Katsumi Aoyagi³, Kazuhiro Tateda²
- 8 Affiliations
- 9 1) Department of General Medicine and Emergency Care, Toho University Omori Medical
- 10 Center, Tokyo, Japan. 2) Department of Microbiology and Infectious Diseases, Toho
- 11 University School of Medicine, Tokyo, Japan. 3) Fujirebio Inc., Tokyo, Japan.
- 13 Keywords
- 14 COVID-19, SARS-CoV2, POCT, Antigen test, immunochromatography.
- 16 Running title
- 17 Evaluation of the rapid SARS-CoV-2 N antigen test
- 19 Corresponding Author:
- 20 Shintaro Yagi, Ph.D.
- 21 Research and Development Division
- 22 Fujirebio Inc.
- 23 51 Komiya-machi, Hachioji, Tokyo, Japan
- 24 TEL +81-42-645-4755
- 25 e-mail: shintaro.yagi@miraca.com

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2122

23

24

25

26

27

28

29

30

Abstract We evaluated the rapid immunochromatographic test for SARS-CoV-2 antigen detection using 16 saliva specimens collected from 6 COVID-19 hospitalized patients, and detected N-antigen in 4 of 7 RT-PCR positive specimens. The POCT antigen test using saliva is highly considered to be a game-changer for COVID-19 diagnosis. Introduction COVID-19 caused by SARS-CoV-2 infection is diagnosed by nucleic acid amplification test, as reverse-transcription polymerase chain reaction (RT-PCR), for viral genome RNA in nasopharyngeal swab specimens. The collection procedure of nasopharyngeal specimens poses a risk of secondary infection to health-care workers. The risk could be reduced if saliva specimens could be used for diagnosis of COVID-19. Recently, several reports indicated that SARS-CoV-2 was detected in saliva specimens of equally or higher sensitivity than the nasopharyngeal specimens[1–3]. We recently developed a rapid antigen detection kit, ESPLINE® SARS-CoV-2 test, for detection of the viral N antigens in nasopharyngeal swabs (manuscript in preparation). The ESPLINE test is an enzyme-immunoassay based on immunochromatographic technology using monoclonal antibodies specific to SARS-CoV and CoV-2 N antigens. In this report, we evaluated the saliva specimens for diagnosis of COVID-19 by RT-PCR and the point of care testing (POCT) antigen test. **Materials and methods** Sets of saliva and nasopharyngeal specimens were collected within several days from 6 COVID-19 patients hospitalized in Omori Hospital, who had been diagnosed by RT-PCR test. Informed consent was obtained from all participants in the study. The study protocol was approved by the Ethics Committee of Faculty of Medicine, Toho University (No. A20028_A20020_A20014_A19099). Saliva was collected by passive drool method

according to previous report[4]. Ct values were obtained by RT-PCR test using N2 probe

according to the manual provided by National Institute of Infectious Diseases[5].

1 SARS-CoV-2 antigen was assessed using ESPLINE kit according to the manufacturer's

instruction (Fujirebio Inc., Tokyo). The procedure is briefly described as follows: specimen

collected by the Swab in the kit was treated with the sample treatment solution.

Approximately 20 μ L of the treated sample was applied to the immunochromatography

cassette, and was developed for 30 minutes. After incubation, test and reference lines

6 were visually assessed.

Results

2

3

4

5

7

8

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

9 SARS-CoV-2 RNA was detected in 13 of 16 (81.3%). On the other hand, RT-PCR detected

RNA in only 7 of 16 saliva specimens (43.8%). No significant difference in RNA copies of

nasopharyngeal specimens between positive and negative RT-PCR results of saliva

specimens was found. When 9 of the 13 RT-PCR positive nasopharyngeal specimens

were examined, SARS-CoV-2 antigen in 7 specimens (77.8% in sensitivity) was detected

by the ESPLINE test. The antigen was detected in 4 of 7 RT-PCR positive saliva specimens

(47.8%)(Figure 1). As shown in previous studies of SARS-CoV-2 antigen tests, sensitivity

of the antigen seems to be correlated with RNA copies concentrations in the specimens⁵

(Manuscript in preparation).

Discussion

Sensitivity of SARS-CoV-2 RT-PCR in saliva specimens was lower than those reported

previously[1,2,4,6–8]. Among several procedures of saliva collection which have been

applied, we chose the passive drool method to reduce the burden of the patients and

the secondary risk to healthcare workers. However, collection procedure should be

examined for further studies. In addition, symptoms, periods after the onset of

symptoms and infection could affect the sensitivity of the RNA detection in saliva. These

factors would also affect the sensitivity of antigen detection using the ESPLINE kit.

This study was carried out using specimens collected from hospitalized patients. The

mechanism and hazard of secondary infection caused by asymptomatic carriers and

super spreaders through biological materials from them have been discussed[9]. To

assess the secondary infection hazards, it would be important to measure infectious

1 virus particles in saliva and nasal fluid. Low prevalence of RNA in saliva specimens from

the hospitalized patients might provide clues to assessment of the secondary infection

3 hazards. To address this issue, mass-screening using POCT tests would be a powerful

4 tool.

2

6

9

10

11

12

15

17

18

19

21

23

2425

26

5 This is the first report of SARS-CoV-2 antigen detection in saliva using a POCT antigen

test. The combination of saliva specimen and rapid antigen detection test could reduce

7 burden of medical settings by decreasing not only the risk of secondary infection, but

8 also time of diagnosis and cost of the specialized expensive equipment. It could be

useful for COVID-19 screening to prevent COVID-19 epidemic by identifying persons

who will spread COVID-19 through saliva.

Funding

13 A part of this research was supported by the Japan Agency for Medical Research and

14 Development under Grant Number JP19fk0108113.

Conflict of Interest

16 SY and KaA are an employee, and the director of Fujirebio, Inc., respectively.

Acknowledgments

Author contributions

20 YI, SY, KaA and KT contributed to design this study. KK, TMa, TM, and SaY contributed to

collect specimens, KoA and YI contributed to conduct and perform RT-PCR and antigen

22 tests, YI, KoA, SY and KaA contributed to analyze data, and SY, YI, KoA and KT

contributed to prepare this manuscript.

Reference

- 1. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior
- 28 oropharyngeal saliva samples and serum antibody responses during infection by
- 29 SARS-CoV-2: an observational cohort study. Lancet Infect Dis **2020**;

- 2. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more sensitive for
- 2 SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. Medrxiv
- 3 **2020**; :2020.04.16.20067835.
- 4 3. Pasomsub E, Watcharananan SP, Boonyawat K, et al. Saliva Sample as a Non-Invasive
- 5 Specimen for the Diagnosis of Coronavirus Disease-2019 (COVID-19): a Cross-Sectional
- 6 Study. Medrxiv **2020**; :2020.04.17.20070045.
- 7 4. To KK-W, Tsang OT, Yip CC-Y, et al. Consistent detection of 2019 novel coronavirus in
- 8 saliva. Clin Infect Dis **2020**;
- 9 5. Shinomiya KSNNSMMTTKKSH. Manual for the Detection of Pathogen 2019 nCoV
- 10 Ver.2.6. 2020.
- 11 6. Williams E, Bond K, Zhang B, Putland M, Williamson DA. Saliva as a non-invasive
- specimen for detection of SARS-CoV-2. J Clin Microbiol **2020**;
- 13 7. Zhong F, Liang Y, Xu J, et al. Continuously High Detection Sensitivity of Saliva, Viral
- Shedding in Salivary Glands and High Viral Load in Patients with COVID-19. Ssrn
- 15 Electron J **2020**;
- 16 8. Chen L, Zhao J, Peng J, et al. Detection of 2019-nCoV in Saliva and Characterization of
- Oral Symptoms in COVID-19 Patients. Ssrn Electron J **2020**;
- 18 9. Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q. Saliva: potential diagnostic value and
- transmission of 2019-nCoV. Int J Oral Sci **2020**; 12:11.
- 21 Legend of Figure 1.

20

25

- 22 Detection of SARS-CoV-2 N antigen in nasopharyngeal swab and saliva specimens.
- 23 Closed circles indicate N antigen positive specimens. Among 16 nasopharyngeal swabs,
- 4 samples without Ag assay data are not plotted.

Figure 1

